2023
Preferences in medications for patients seeking treatment for opioid use disorder: A conjoint analysis
Muthulingam D, Hassett T, Madden L, Bromberg D, Fraenkel L, Altice F. Preferences in medications for patients seeking treatment for opioid use disorder: A conjoint analysis. Journal Of Substance Use And Addiction Treatment 2023, 154: 209138. PMID: 37544510, DOI: 10.1016/j.josat.2023.209138.Peer-Reviewed Original ResearchMeSH KeywordsBayes TheoremBuprenorphineCOVID-19Cross-Sectional StudiesHumansOpioid-Related DisordersPandemicsConceptsOpioid use disorderRoute of administrationPatient preferencesUse disordersSymptom reliefTreatment preferencesSide effectsCross-sectional observational studyTreatment-seeking peopleChi-squared analysisOral medicationsPublic health crisisOUD treatmentTreatment uptakeWithdrawal symptomsOpioid epidemicObservational studyTreatment decisionsSTROBE checklistSustainability of treatmentPatientsMedicationsHealth professionalsUtility scoresLarger study
2020
Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine
Meteliuk A, Galvez de Leon SJ, Madden LM, Pykalo I, Fomenko T, Filippovych M, Farnum SO, Dvoryak S, Islam ZM, Altice FL. Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine. Journal Of Substance Use And Addiction Treatment 2020, 121: 108164. PMID: 33191004, PMCID: PMC7769928, DOI: 10.1016/j.jsat.2020.108164.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyTake-home dosingInterim guidanceShort-term overall mortalityOpioid agonist treatment programPerson clinical encountersOAT deliveryAgonist therapyOverall mortalityCOVID-19 transmissionPatient dropoutOAT patientsNaloxone distributionOverdose educationClinical practiceClinic interactionsTreatment programClinical encountersPatientsCliniciansCOVID-19COVID-19 pandemicOverdosesDosingPrevious yearThe real‐world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine
Farnum SO, Makarenko I, Madden L, Mazhnaya A, Marcus R, Prokhorova T, Bojko MJ, Rozanova J, Dvoriak S, Islam Z, Altice FL. The real‐world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine. Addiction 2020, 116: 83-93. PMID: 32428276, PMCID: PMC7674222, DOI: 10.1111/add.15115.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOAT discontinuationAgonist therapyTreatment retentionIndependent predictorsHIV epidemicCost-effective HIV prevention strategyMethadone maintenance treatment patientsObservational longitudinal cohort studySpecialty addictions treatmentBuprenorphine maintenance treatmentHigh dosageHIV prevention strategiesLongitudinal cohort studyOpioid-dependent peopleTreatment discontinuationCohort studyMaintenance treatmentMale sexTreatment patientsPrevention strategiesDiscontinuationYounger ageCenter settingAddiction treatmentAdherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults
Viera A, Bromberg DJ, Whittaker S, Refsland BM, Stanojlović M, Nyhan K, Altice FL. Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults. Epidemiologic Reviews 2020, 42: 41-56. PMID: 32239206, PMCID: PMC8087870, DOI: 10.1093/epirev/mxaa001.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersYoung adultsAssociation of ageFull-text reviewRetention of adolescentsConcurrent substance useNegative health outcomesMOUD retentionOpioid epidemicInclusion criteriaHealth outcomesYounger ageAge groupsMOUDSubstance useAdherenceGood evidenceAdultsMedicationsDisordersAdolescentsSearch criteriaAgeOutcomes
2018
Opioid Agonist Treatment and Improved Outcomes at Each Stage of the HIV Treatment Cascade in People Who Inject Drugs in Ukraine
Mazhnaya A, Marcus R, Bojko MJ, Zelenev A, Makarenko I, Pykalo I, Filippovych S, Dvoriak S, Altice FL. Opioid Agonist Treatment and Improved Outcomes at Each Stage of the HIV Treatment Cascade in People Who Inject Drugs in Ukraine. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 288-295. PMID: 30312275, PMCID: PMC8215524, DOI: 10.1097/qai.0000000000001827.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentHIV treatment cascadeTreatment cascadeAgonist treatmentIndependent factorsHepatitis C virus testingOpioid-dependent PWIDOpioid use disorderClinical care settingsLogistic regression modelsOAT coverageAntiretroviral therapyHIV careUNAIDS 90HIV preventionImproved outcomesTreatment strategiesCare settingsVirus testingNationwide studyPWIDUse disordersOAT expansionHIVCareConcurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine
Makarenko I, Mazhnaya A, Marcus R, Pykalo I, Madden L, Filippovich S, Dvoriak S, Altice FL. Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine. Journal Of Substance Use And Addiction Treatment 2018, 87: 1-8. PMID: 29471921, PMCID: PMC5826566, DOI: 10.1016/j.jsat.2018.01.007.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentMethadone maintenance treatmentConcurrent illicit drug useOAT patientsIllicit drug useDrug injectionDrug useAgonist treatmentUse disordersMultivariable logistic regressionConcurrent drug useOngoing drug usePolysubstance use disorderAlcohol use disorderMaintenance treatmentIndependent correlatesBMT programSevere opioidDrug injectingPatientsHealth outcomesTreatment dropoutAlcohol dependenceInjection initiationYounger age
2017
Using nominal group technique among clinical providers to identify barriers and prioritize solutions to scaling up opioid agonist therapies in Ukraine
Madden L, Bojko MJ, Farnum S, Mazhnaya A, Fomenko T, Marcus R, Barry D, Ivanchuk I, Kolomiets V, Filippovych S, Dvoryak S, Altice FL. Using nominal group technique among clinical providers to identify barriers and prioritize solutions to scaling up opioid agonist therapies in Ukraine. International Journal Of Drug Policy 2017, 49: 48-53. PMID: 28957756, DOI: 10.1016/j.drugpo.2017.07.025.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyNominal group techniqueAgonist therapyBuprenorphine maintenance treatmentAddiction treatment approachesImplementation science strategiesOAT servicesMaintenance treatmentClinical providersTreatment approachesTreatment servicesNGT discussionRegional controlTherapyCliniciansGroup techniqueStructural barriersRetention in medication-assisted treatment programs in Ukraine—Identifying factors contributing to a continuing HIV epidemic
Dumchev K, Dvoryak S, Chernova O, Morozova O, Altice FL. Retention in medication-assisted treatment programs in Ukraine—Identifying factors contributing to a continuing HIV epidemic. International Journal Of Drug Policy 2017, 48: 44-53. PMID: 28800420, PMCID: PMC5603251, DOI: 10.1016/j.drugpo.2017.05.014.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentMedication-assisted treatment programTB test resultsTwelve-month retentionCare delivery systemCorrelates of retentionEvidence-based strategiesTB patientsMultivariable analysisOpioid dependenceAgonist treatmentHIV transmissionClinical recordsHIV epidemicOAT programsPatient retentionHigher dosingHigh dosesTreatment programPatientsSurvival analysis methodsDosingTuberculosisElectronic monitoring systemTreatmentPrimary healthcare-based integrated care with opioid agonist treatment: First experience from Ukraine
Morozova O, Dvoriak S, Pykalo I, Altice FL. Primary healthcare-based integrated care with opioid agonist treatment: First experience from Ukraine. Drug And Alcohol Dependence 2017, 173: 132-138. PMID: 28242537, PMCID: PMC5545131, DOI: 10.1016/j.drugalcdep.2016.12.025.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineCross-Sectional StudiesDelivery of Health Care, IntegratedFemaleHealth Services ResearchHIV InfectionsHumansMaleMethadoneMiddle AgedOpiate Substitution TreatmentOpioid-Related DisordersPatient DropoutsPatient SatisfactionPilot ProjectsPrimary Health CareQuality of LifeSubstance Abuse, IntravenousUkraineConceptsOpioid agonist therapyPrimary healthcare clinicsIntegrated carePHC staffHIV patientsHIV epidemicOAT patientsOpioid agonist treatmentStandard of careAddiction treatment settingsAgonist therapyObservational cohortMiddle-income countriesAgonist treatmentPrimary careComprehensive healthcare servicesPWIDHealthcare clinicsAddiction clinicPatientsTreatment settingsDrug usersPilot studyCareHealthcare services
2016
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Annals Of Internal Medicine 2016, 165: 625-634. PMID: 27537841, DOI: 10.7326/m16-0816.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntiviral AgentsBenzofuransBuprenorphineBuprenorphine, Naloxone Drug CombinationDouble-Blind MethodDrug CombinationsDrug Resistance, ViralFemaleGenotypeHepatitis C, ChronicHumansImidazolesMaleMedication AdherenceMethadoneMiddle AgedOpiate Substitution TreatmentOpioid-Related DisordersQuinoxalinesRecurrenceSubstance Abuse, IntravenousYoung AdultConceptsDeferred-treatment groupOpioid agonist therapyImmediate treatment groupHepatitis C virus infectionC virus infectionElbasvir-grazoprevirDrug useProbable reinfectionAgonist therapyHCV infectionViral recurrenceAdverse eventsVirus infectionChronic HCV genotype 1Double-blind trialGenotype 3 infectionTreatment-naive patientsHCV genotype 1Interferon-free HCV treatmentOngoing drug useVirologic responseHCV therapyHCV treatmentPrimary outcomeGenotype 1Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine
Makarenko I, Mazhnaya A, Polonsky M, Marcus R, Bojko MJ, Filippovych S, Springer S, Dvoriak S, Altice FL. Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine. Drug And Alcohol Dependence 2016, 165: 213-220. PMID: 27370527, PMCID: PMC5094181, DOI: 10.1016/j.drugalcdep.2016.06.011.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentAdjusted odds ratioOpioid use disorderAgonist treatmentUse disordersSignificant adjusted odds ratiosMultivariable logistic regressionHIV-negative statusPatient-level interventionsOpioid-dependent peopleInjection frequencyHIV statusOdds ratioRecent overdoseIndependent factorsPWIDLogistic regressionPrevious imprisonmentHigher injection frequencySignificant correlatesPrior incarcerationFamily supportDisordersDrugsIntervention
2015
Balancing access and safety in prescribing opioid agonist therapy to prevent HIV transmission
Bachireddy C, Weisberg DF, Altice FL. Balancing access and safety in prescribing opioid agonist therapy to prevent HIV transmission. Addiction 2015, 110: 1869-1871. PMID: 26464200, DOI: 10.1111/add.13055.Peer-Reviewed Original ResearchTreatment Readiness, Attitudes Toward, and Experiences with Methadone and Buprenorphine Maintenance Therapy Among People Who Inject Drugs in Malaysia
Vijay A, Bazazi AR, Yee I, Kamarulzaman A, Altice FL. Treatment Readiness, Attitudes Toward, and Experiences with Methadone and Buprenorphine Maintenance Therapy Among People Who Inject Drugs in Malaysia. Journal Of Substance Use And Addiction Treatment 2015, 54: 29-36. PMID: 25841703, PMCID: PMC4758679, DOI: 10.1016/j.jsat.2015.01.014.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAge of OnsetAgedAttitudeBuprenorphineEthnicityFemaleHumansMalaysiaMaleMethadoneMiddle AgedNarcoticsNeedle SharingNeedle-Exchange ProgramsOpiate Substitution TreatmentPatient Acceptance of Health CareStress, PsychologicalSubstance Abuse Treatment CentersSubstance Abuse, IntravenousYoung AdultConceptsOpioid maintenance therapyBuprenorphine maintenance therapyMaintenance therapyTreatment readinessNeedle/syringe exchange programsSharing of needlesMultivariable linear regressionSyringe exchange programsCompulsory drug detention centersMajority of subjectsReadiness scoresOpioid dependencePatients' attitudesPrimary careMethadoneTreatment settingsStress symptom severityBuprenorphineIndian ethnicityAdult populationSymptom severityOlder agePast monthTherapyDrugs
2014
Buprenorphine Maintenance Treatment Retention Improves Nationally Recommended Preventive Primary Care Screenings when Integrated into Urban Federally Qualified Health Centers
Haddad MS, Zelenev A, Altice FL. Buprenorphine Maintenance Treatment Retention Improves Nationally Recommended Preventive Primary Care Screenings when Integrated into Urban Federally Qualified Health Centers. Journal Of Urban Health 2014, 92: 193-213. PMID: 25550126, PMCID: PMC4338126, DOI: 10.1007/s11524-014-9924-1.Peer-Reviewed Original ResearchConceptsBuprenorphine maintenance therapyPrimary care providersPrimary health care settingsHealth care screeningQualified health centersHealth care settingsOpioid dependenceHealth centersPsychiatric specialistsUrban Federally Qualified Health CenterFederally Qualified Health CentersOpioid-dependent womenPrimary care screeningObservational cohort studyOpioid-dependent patientsHuman immunodeficiency virusProportion of subjectsHealth care indicatorsHealth care outcomesImproved health outcomesElectronic health recordsUrban FQHCsHepatitis CMaintenance therapyCohort studySelf-Management of Buprenorphine/Naloxone Among Online Discussion Board Users
Brown SE, Altice FL. Self-Management of Buprenorphine/Naloxone Among Online Discussion Board Users. Substance Use & Misuse 2014, 49: 1017-1024. PMID: 24779501, PMCID: PMC5592159, DOI: 10.3109/10826084.2014.888449.Peer-Reviewed Original Research
2013
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice
Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Review Of Clinical Pharmacology 2013, 6: 249-269. PMID: 23656339, PMCID: PMC4198941, DOI: 10.1586/ecp.13.18.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyAntiretroviral therapyDrug interactionsAgonist therapyHIV medicationsHepatitis C virus medicationsHepatitis C virus (HCV) treatmentActive antiretroviral therapyC virus treatmentPharmacodynamic drug interactionsImportant clinical consequencesReview of abstractsHCV therapyAntiretroviral agentsPharmacodynamic interactionsPharmacological interactionsHIV therapyClinical consequencesVirus treatmentClinical practiceFollowing keywordsTherapyClinical implicationsMedicationsMethadoneIntegrating buprenorphine maintenance therapy into federally qualified health centers: Real-world substance abuse treatment outcomes
Haddad MS, Zelenev A, Altice FL. Integrating buprenorphine maintenance therapy into federally qualified health centers: Real-world substance abuse treatment outcomes. Drug And Alcohol Dependence 2013, 131: 127-135. PMID: 23332439, PMCID: PMC3674170, DOI: 10.1016/j.drugalcdep.2012.12.008.Peer-Reviewed Original ResearchConceptsQualified health centersSubstance abuse counselingHealth centersBuprenorphine maintenance treatment programCocaine useBuprenorphine maintenance therapyConcomitant cocaine useOpioid-dependent patientsMaintenance treatment programReal-world effectivenessSubstance abuse treatment outcomesElectronic health recordsHCV infectionMaintenance therapyPsychiatric comorbidityMean ageDependent patientsPsychiatric medicationsClinical trialsTreatment outcomesMood disordersFamily practitionersMore weeksTreatment programBMT
2012
Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners
Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners. PLOS ONE 2012, 7: e38335. PMID: 22719814, PMCID: PMC3365007, DOI: 10.1371/journal.pone.0038335.Peer-Reviewed Original ResearchConceptsMaximum viral suppressionOpioid dependenceViral suppressionGlobal health qualityMaximal viral suppressionHIV treatment outcomesBuprenorphine/naloxoneCopies/mLChronic relapsing diseaseDSM-IV criteriaAntiretroviral therapyOpioid useProspective trialProspective studyRelapsing diseaseOpioid dependentsTreatment outcomesHIV-1HIVNLXHealth qualityTherapyWeeksSuppressionGroupRetention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence
Schwarz R, Zelenev A, Bruce RD, Altice FL. Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence. Journal Of Substance Use And Addiction Treatment 2012, 43: 451-457. PMID: 22534003, PMCID: PMC3419304, DOI: 10.1016/j.jsat.2012.03.008.Peer-Reviewed Original ResearchConceptsBuprenorphine maintenance treatmentHealthcare utilizationED utilizationEmergency department usageOpioid-dependent patientsEmergency department utilizationLate-stage diseaseTreatment-seeking patientsBuprenorphine treatmentChart reviewPerson yearsED useMaintenance treatmentOpioid dependenceDependent patientsPrimary careHospitalizationDrug usersNegative binomial regressionBinomial regressionPatientsComparison of timeTreatmentAverage lengthStay
2011
Hepatic Safety and Lack of Antiretroviral Interactions With Buprenorphine/Naloxone in HIV-Infected Opioid-Dependent Patients
Vergara-Rodriguez P, Tozzi MJ, Botsko M, Nandi V, Altice F, Egan JE, O'Connor PG, Sullivan LE, Fiellin DA. Hepatic Safety and Lack of Antiretroviral Interactions With Buprenorphine/Naloxone in HIV-Infected Opioid-Dependent Patients. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s62-s67. PMID: 21317596, DOI: 10.1097/qai.0b013e31820a820f.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneOpioid-dependent patientsMedian aspartate aminotransferasePharmacodynamic interactionsAspartate aminotransferaseBup/ALT valuesAlanine aminotransferaseBUP/NXOpioid-dependent HIVProspective cohort studyHepatic safetyHepatitis CCohort studyHepatic toxicityHIVPatientsAtazanavirNaloxonePrior reportsExposure measuresSignificant decreaseAminotransferaseSignificant changesTreatment